The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
The Biden administration recently launched the Global Health Security Strategy, a new effort to improve the country’s ability to prevent, detect, and respond to the spread of infectious diseases, according to NPR. With this new strategy, the White House strives to make the US better prepared for future pandemics, outbreaks, and biological threats, regardless of where they occur. Consequently, the US will also be expanding its health security partnerships to 50 countries worldwide; the US will help these countries improve their abilities to identify and respond to diseases, including improved testing, surveillance, lab capacity, and immunizations. However, some experts worry the new strategy does not go far enough and financial realities will limit its impact. The new plan, which is based on lessons learned from the COVID-19 pandemic, will roll out over 5 years.
Lawmakers zeroed in on the risks of massive consolidation in health care on Tuesday during the first congressional hearing on the Change Healthcare hack, according to Axios. Lawmakers expressed concerns about the impact of mergers forming health care giants like UnitedHealth Group, Change Healthcare’s parent company, after the late February attack against Change Healthcare, the country’s largest medical claims processor, halted payments and crippled operations at some hospitals and clinics. During the hearing, several lawmakers expressed frustration that UnitedHealth did not send a representative or provide answers to key questions; UnitedHealth CEO Andrew Witty is expected to testify soon before the Senate Finance Committee. Although Congress is in the early stages of forming a possible response, lawmakers’ comments suggested the possibility of crackdowns on vertical mergers that have allowed health care companies to expand their reach.
The FDA recently announced the recall of HeartMate II and HeartMate 3, a pair of heart devices linked to hundreds of injuries and at least 14 deaths, according to KFF Health News. The recalled devices are mechanical pumps that help the heart pump blood when it cannot do so on its own; the devices are implanted in patients with end-stage heart failure. The recall affects nearly 14,000 devices. According to the recall notice, the devices can cause a buildup of biological material that reduces the ability to help the heart circulate blood and keep patients alive; the buildup accumulates gradually and can appear 2 years or more after a device is implanted. The FDA advised doctors to watch for low-flow alarms on the devices and, if an obstruction is present, to either monitor the patient or perform surgery to implant a stent, release the blockage, or replace the pump. Despite the recall, the devices are not currently being removed from the market.
National Data Show Rising Risk, Cost of CKD in Patients With Acute Myocardial Infarction
April 10th 2025A series of new studies from the National Kidney Foundation Spring Clinical Meeting exhibit the association between impaired kidney function and prolonged hospital stays, higher charges, and greater resource utilization.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Inflammatory Diets Raise Risk of Brain Disorders
April 10th 2025Vegetables, fish oil, fruit, and high-fiber foods have anti-inflammatory effects, while low-fiber bread and animal fats are associated with pro-inflammatory effects. Diets heavier on these pro-inflammatory foods may be associated with higher risks of brain disorders.
Read More
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More